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Background: Ganoderma lucidum is a popular medicinal mushroom used for promoting health and longevity in
Asian countries. Previously, we reported that a water-soluble extract from a culture medium of Ganoderma lucidum
mycelia (MAK) exerts antioxidative and cerebroprotective effects against ischemia–reperfusion injury in vivo. Here,
we evaluated the antidepressant and anxiolytic activities of MAK in rats.
Methods: MAK (0.3 or 1 g/kg, p.o.) was administered in the experimental animals 60 min before the forced
swimming, open-field, elevated plus-maze, contextual fear-conditioning, and head twitch tests. Additionally, the
mechanisms involved in the antidepressant-like action of MAK were investigated by the serotonin precursor
5-hydroxy-L-tryptophan (5-HTP)- or 5-HT2A agonist (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride
(DOI)-induced head twitch responses.
Results: Treatment with MAK (1 g/kg) exhibited antidepressant-like effects in the forced swimming test, attenuated
freezing behavior in the contextual fear-conditioning test, and decreased the number of head twitches induced by DOI,
but not with 5-HTP. No significant response was observed in locomotion or anxiety-like behavior, when the animals were
evaluated in the open-field or elevated plus-maze test, respectively.
Conclusions: These data suggest that MAK has antidepressant-like potential, which is most likely due to the antagonism
of 5-HT2A receptors, and possesses anxiolytic-like effects toward memory-dependent and/or stress-induced anxiety in rats.
Keywords: Anxiety, Depression, Ganoderma lucidum mycelia, Locomotion, Memory, 5-HT2A receptorsBackground
Major depressive disorder is a common, recurrent men-
tal disease characterized by a negative mood and loss of
interest or pleasure in the normal activities of daily life.
It is often accompanied by a broad range of symptoms,
including a decline in cognitive function, sleep disturb-
ance and recurrent suicidality, which affects the quality-
of-life (QoL) and mortality of patients. Experimental and
clinical studies have suggested that major depression
may be caused at least in part by the metabolic dysregu-
lation of monoaminergic (particularly serotonin and
noradrenaline) systems in the brain [1]. Drugs that* Correspondence: okazaki@josai.ac.jp
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reproduction in any medium, provided the orincrease the levels of monoamines, such as tricyclic anti-
depressants (TCAs), selective serotonin reuptake inhibi-
tors (SSRIs), and serotonin and noradrenaline reuptake
inhibitors (SNRIs), are the mainstays of depression ther-
apy. However, these conventional, commercially available
antidepressants provide only partial remission and fre-
quently produce adverse effects [2]. Therefore, not all
of the neurological pathogeneses of depression can be
explained by the metabolic dysfunction of monoamines.
As a result of these limitations, there is an appreciable
unmet medical need for rapid, safe, and more effective
antidepressants.
Recently, plant extracts have drawn the attention of re-
searchers because of the importance in discovering novel
antidepressant agents. Several herbal medicines (e.g., Panax
notoginseng [3], Asparagus racemosus [4], Rosmarinusral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have antidepressant activity comparable with prescription
medicines but with fewer side effects.
Ganoderma lucidum (G. lucidum) is a popular medi-
cinal fungus known as Lingzhi mushroom in China. It
has long been known for its beneficial effects on human
health and longevity in Asian countries. G. lucidum
has been shown to have several pharmacological effects
(e.g., antitumor, immunomodulatory, anti-inflammatory,
antidiabetic, antioxidative), which are supported by stud-
ies on various bioactive compounds isolated from the
fruiting bodies and mycelia of this fungus [7]. A water-
soluble extract prepared from the culture medium of
G. lucidum mycelia (MAK) has a 17-year history of making
appreciable contributions to consumers’ health as a safe,
functional food. The extract contains various types of
constituents, such as polysaccharides, including β-
glucans, triterpenes, and lignin derived from the culture
medium and its digestion products by the mycelia.
MAK has been reported to have antitumor [8] and
radioprotective effects [9].
Previously, we demonstrated that MAK has antioxi-
dant activities and neuroprotective effects in vivo. Orally
administered MAK can prevent ischemia–reperfusion-
induced oxidative damage to neuronal cells, and reduce
the size of cerebral infarcts in animal models [10,11].
However, until now, the antidepressant-like effects of
MAK have not been assessed.
Therefore, the study aimed to assess the antidepressant-
like and anxiolytic-like activities of MAK in rats. We
performed the forced swimming test together with
open-field test to evaluate antidepressant-like activity,
and the elevated plus-maze test and contextual fear-
conditioning test to evaluate anxiolytic-like activity of
MAK. Furthermore, to ascertain if the antidepressant-
like effect of MAK is mediated by the serotonergic
system, we examined the effect of MAK on 5-hydroxy-




All experiments were conducted in accordance with
the guidelines set by the National Institutes of Health
(Bethesda, MD, USA) and approved by the Animal
Investigation Committee of Josai University (number
H23005). All possible efforts were made to minimize
the number of animals utilized and their suffering.
Animals
Male Sprague–Dawley rats (250–300 g) were purchased
from Sankyo Labo Service Co. Inc. (Tokyo, Japan).
Three or four animals were housed per cage in a
temperature-controlled environment (23 ± 0.5°C) with a12-h light–dark cycle (light on at 7 am) with food and
water ad libitum. One hundred and thirty-three rats
(forced swimming test, 25; open-field test, 21; elevated
plus-maze test, 28; contextual fear-conditioning test, 23;
5-HTP-induced head-twitches, 18; DOI-induced head-
twitches, 18) were used in the present study.Drug treatment
MAK was provided by Noda Shokukin-kogyo Co. Ltd.
(Noda, Japan). The preparation of MAK (overall yield,
≈ 10%) was as follows: a pure culture of G. lucidum
mycelia was inoculated into a solid culture medium that
was composed of bagasse and defatted rice bran and
cultured until just before the formation of the fruit body
(for 3–4 months); subsequently, the entire medium
overgrown with G. lucidum mycelia was extracted with
hot water, and then the extract was sterilized by filtra-
tion and lyophilized for powderization. Fluvoxamine
maleate, imipramine hydrochloride, 5-hydroxy-L-tryp-
tophan (5-HTP), and (±)-1-(2,5-dimethoxy-4-iodophenyl)-
2-aminopropane hydrochloride (DOI) were purchased
from Sigma–Aldrich (St Louis, MO, USA). Drugs were
dissolved in distilled water except 5-HTP and DOI, which
were dissolved in saline. MAK (0.3 or 1 g/kg), imipramine
(10 mg/kg) as a positive control, or distilled water was
administered orally 60 min before the forced swimming
test, open-field test, elevated plus-maze test, or contextual
fear-conditioning test.Forced swimming test
The experiment was carried out according to the
method described by Porsolt et al. [12] with a minor
modification. Briefly, on the first day (pre-test session),
rats were placed individually in a clear cylinder (20-cm
diameter, 50-cm height) that contained water (25 ± 1°C)
to a depth of 25 cm and forced to swim for 15 min. Sub-
sequently, rats were removed from the cylinder, dried
with towels, and warmed by a heater before being
returned to their home cages. The water in the tank was
replaced after it was used by each animal. On the follow-
ing day (test session), rats were placed back into the
cylinder for 5 min. A 5-s sampling procedure [13] was
utilized for scoring the behaviors (i.e., immobility, climb-
ing, and swimming). Immobility was noted if the rat
remained floating in the water without struggling and
only made movements to keep its head or nose above
the water. “Climbing” was defined as the animal making
upwardly directed vigorous movements of the forepaws
usually along the cylinder wall while keeping its head
and shoulders above the water. “Swimming” was defined
as horizontal movement throughout the cylinder with a
more vigorous motion of all four paws than that neces-
sary to merely maintain the head above the water.
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Locomotor activity was assessed by the open-field test
following a protocol described previously [14]. The
open-field apparatus comprised a gray box (70 cm × 70
cm; 40-cm height) divided into 49 squares of equal area
(10 cm × 10 cm). At the start of each test, rats were
placed in the center of the open field and allowed to
explore the inside of the box. Behavior was monitored
using a video camera that was positioned above the
apparatus during the 30-min test period. The number of
lines crossing was analyzed automatically by a video-
tracking system with a software package (CompACT
VAS, Muromachi Kikai, Tokyo, Japan). The apparatus
was cleaned with isopropanol after each test.
Elevated plus-maze test
To examine the exploratory behavior of rats, the ele-
vated plus-maze was performed as described previously
[15] with minor modifications. The apparatus (which
was raised 50 cm above the floor) consisted of two op-
posing open arms (50-cm long × 10-cm wide) and two
opposing closed arms of the same size surrounded by
side walls (40-cm high) that extended from the central
platform (10 cm × 10 cm). At the start of each test, rats
were placed individually on the central platform, and
their behaviors monitored by the video camera for 10
min. The number of entries for each arm and the time
spent in each arm were recorded and analyzed automat-
ically using CompACT VAS. The number of closed arm
entries was used as an index of locomotor activity. The
percentage of open arm entries (open arm entries × 100/
total arm entries) and percentage of time spent in open
arm (time spent in open arm × 100/time spent in open
and closed arms) were used as indices of anxiety.
Contextual fear-conditioning test
A footshock chamber that consisted of a plexiglass rect-
angular box (30 cm × 30 cm × 30 cm) with a floor of 18
stainless-steel rods (6-mm diameter) wired to a shock
generator (LE 100-26, Panlab, Barcelona, Spain) was
used to evaluate memory-dependent fear-related behav-
ior. The experiment was done during 2 consecutive days.
On the first day, each rat was exposed to the shock
chamber for 5 min for adaptation to the experimental
conditions, and then the rat received five inescapable
electrical footshocks for a total of 2.5 min (0.5 mA, 2-s
duration, repeated every 30 s). Five minutes after the last
footshock, the rat was returned to his home cage. The
following day (24 h later), the rat was placed into the
same footshock chamber without footshocks. In the 10-
min observation period, freezing behavior was recorded
using a time-sampling procedure [16] in which animal
behavior was classified as “freezing” or “activity” at 5-s
intervals. Freezing behavior was defined as the absenceof all movement with the exception of movements re-
lated to respiration and whisker movements [16]. The
percentage scores for freezing were calculated for a 10-min
observation period. Analyses of freezing behavior were
evaluated by an investigator blinded to the treatment
protocol.
Head-twitch test
The head-twitch test was carried out according a
method described by Rojas-Corrales et al. [17] with
minor modifications. Rats were orally treated with MAK
(1 g/kg) or fluvoxamine (10 mg/kg) 60 min before intra-
peritoneal injection of 5-HTP (200 mg/kg). Immediately
after 5-HTP administration, the rat was placed into an
observation cage (30 cm × 25 cm × 18 cm) and the cu-
mulative number of head twitches (i.e., rapid movements
of the head with little or no involvement of the trunk)
counted by an observer blinded to the study protocol for
30 min. Similarly, the effect of MAK on DOI (3 mg/kg)-
induced head-twitch responses was measured.
Statistics analyses
Data are the mean ± S.E.M. Significant differences be-
tween groups were evaluated using one-way analysis of
variance (ANOVA), followed by the Tukey’s post hoc
test except for contextual fear-conditioning test, which
by the Bonferroni’s test. P < 0.05 was considered signi-
ficant. The statistical analysis was conducted using




Figure 1 illustrates the effects of MAK on immobility,
climbing, and swimming behaviors in the forced swim-
ming test. MAK (1 g/kg) and the classical antidepressant
imipramine reduced immobility (23% and 35%, respect-
ively) in the forced swimming test compared with the
distilled water-treated control group. One-way ANOVA
revealed significant differences in immobility ([F(3,21) =
11.09, P < 0.01]). Post hoc analyses indicated significant dif-
ferences between the control group and the MAK (1 g/kg)-
treated group (P < 0.05) and the imipramine-treated group
(P < 0.01). Furthermore, one-way ANOVA revealed a sig-
nificant differences in climbing ([F(3,21) = 7.33, P < 0.01]).
Post hoc analyses indicated a significant difference be-
tween the control group and the imipramine-treated
group (P < 0.01), but the difference between the control
group and MAK-treated group was not significant.
Open-field test
To exclude the possibility of a false-positive effect in the
forced swimming test, the effects of MAK on locomotor
activity were tested. One-way ANOVA revealed significant
Figure 1 Effects of MAK on the duration of immobility,
climbing and swimming behaviors in the forced swimming
test. Behaviors were scored every 5 s for a 5-min observation period.
Results are the mean ± S.E.M. The number of rats per group was:
control group, n = 8; MAK (0.3 g/kg)-treated group, n = 6; MAK
(1 g/kg)-treated group, n = 6; imipramine-treated group, n = 5.
*P < 0.05, **P < 0.01 compared with the control group, one-way
analysis of variance followed by Tukey’s test.
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Post hoc analyses indicated a significant difference be-
tween the control group and the imipramine-treated
group (P < 0.05) (Figure 2).
Elevated plus-maze test
No significant differences were detected for rats treated
with MAK or imipramine compared with control rats
on the number of closed arm entries ([F(3,24) = 0.79,
P = 0.51]), the percentage of open arm entries ([F(3,24)
= 0.08, P = 0.97]), or the percentage of time spent in
open arms ([F(3,24) = 0.09, P = 0.97]) (Table 1).
Contextual fear-conditioning test
In the contextual fear-conditioning test, the freezing rate
was decreased to 49.6 ± 8.5% in the MAK (1 g/kg)-treatedFigure 2 Effects of MAK on locomotor activity in the open-field
test. Results are the mean ± S.E.M. The number of crossings recorded
for a 30-min period. The number of rats per group was: control group,
n = 6; MAK (0.3 g/kg)-treated group, n = 5; MAK (1 g/kg)-treated group,
n = 5; imipramine-treated group, n = 5. *P < 0.05 compared with the
control group, one-way analysis of variance followed by Tukey’s test.group compared with 72.8 ± 3.5% in the control group
(Figure 3). One-way ANOVA revealed significant differ-
ences in freezing behavior ([F(2,20) = 8.39, P < 0.01]).
Post hoc analyses indicated a significant difference be-
tween the control group and the MAK (1 g/kg)-treated
group (P < 0.05).
5-HTP- or DOI-induced head twitches
Figure 4 shows the effect of MAK (1 g/kg) on 5-HTP-
induced head twitches. One-way ANOVA revealed signifi-
cant differences in 5-HTP-induced head twitches ([F(2,15)
= 33.4, P < 0.01]). Post hoc analyses indicated significant
differences between the control group and fluvoxamine-
treated group (P < 0.01), but the difference between the
control group and MAK-treated group was not signifi-
cant (P = 0.33). Figure 5 demonstrates the effect of
MAK on DOI-induced head twitches. One-way ANOVA
revealed significant differences in DOI-induced head
twitches ([F(2,15) = 25.2, P < 0.01]). Post hoc analyses
indicated significant differences between the control
group and MAK-treated group (P < 0.01).
Discussion
In the present study, we provided evidence, for the first
time, that acute oral administration of MAK (a func-
tional food derived from G. lucidum mycelia) exerts a
significant antidepressant-like effect in rats, and that this
effect can be observed in the forced swimming test. The
forced swimming test is the most widely used paradigm
for screening potential antidepressants in rodents. A sig-
nificant correlation between the efficacy and effective-
ness of therapy has been demonstrated in the forced
swimming test [12]. Various antidepressants, such as
TCAs, SSRIs, and SNRIs, have been demonstrated to re-
duce immobility without altering locomotor activity [18].
The present study showed that MAK significantly reduced
immobility in the forced swimming test. Psychostimulants,
such as amphetamine and caffeine, also reduce immo-
bility in the forced swimming test with increasing gen-
eral activity [12], so MAK was evaluated for its effects
on locomotor activity in the open-field test to exclude a
false-positive effect. At a dose that showed a significant
decrease in immobility in the forced swimming test
(1 g/kg), MAK did not change locomotor activity. These
results suggest that the MAK-induced decrease in
immobility in the forced swimming test is caused by
an antidepressant-like effect rather than a locomotor-
enhancing effect.
To evaluate the anxiety-like effect of MAK, the con-
textual fear-conditioning test and elevated plus-maze
test as memory-dependent and -independent tasks, respect-
ively, were undertaken [19,20]. In the contextual fear-
conditioning test, the MAK (1 g/kg)-treated group showed
a significant decrease in freezing behavior compared with






spent in open arm
Control 18.0 ± 4.4 50.2 ± 4.0 36.2 ± 7.8
MAK (0.3 g/kg) 23.0 ± 4.2 47.8 ± 5.8 34.5 ± 11.0
MAK (1 g/kg) 15.0 ± 3.5 47.8 ± 6.1 42.0 ± 13.9
Imipramine 18.8 ± 4.1 46.1 ± 6.0 41.1 ± 13.7
Results are the mean ± S.E.M. The number of rats per group was: control group, n = 7; MAK (0.3 g/kg)-treated group, n = 6; MAK (1 g/kg)-treated group, n = 9;
imipramine-treated group, n = 6.
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index of anxiety (% open arm entries and % time spent in
open arm) or locomotor activity (closed arm entries) in the
elevated plus-maze test. Conditioned fear-induced freezing
behavior has been demonstrated to be decreased by repre-
sentative anxiolytic agents such as benzodiazepines [21]
and SSRIs [22]. Similarly, the percentage of time spent in
the open arms in the elevated plus-maze test is increased
by treatment with clinically effective anxiolytic agents but is
decreased by anxiogenic agents [23]. However, the elevated
plus-maze test is known to exhibit remarkable variability,
and sometimes paradoxical patterns in experimental results
using 5-HT-related agents have been obtained [24,25].
Indeed, the elevated plus-maze test could not detect the
anxiolytic-like effects of 5-HT2 receptor antagonists such as
ketanserin, mianserin, and MDL-100907 in previous studies
[26,27]. Collectively, the elevated plus-maze test might not
have been suitable to assess the anxiolytic effect of MAK,
which may possess anxiolytic-like effects toward memory-
dependent and/or stress-induced anxiety.Figure 3 Effects of MAK on freezing behavior in the contextual
fear-conditioning test. Results are the mean ± S.E.M. of freezing
scored for a 10-min observation period. The number of rats per group
was: control group, n = 9; MAK(0.3 g/kg)-treated group, n = 6; MAK
(1 g/kg)-treated group, n = 8. *P < 0.05 compared with the control
group, one-way analysis of variance followed by Bonferroni’s test.The head-twitch response is defined as a rapid move-
ment of the head and neck. It is a useful index for asses-
sing the effects of drugs on central serotonergic activity
in vivo in rodent experiments. The stereotypical behavior
is induced by the serotonin precursor 5-HTP via an in-
crease of serotonin levels in the synaptic clefts [28] and
the subsequent indirect activation of 5-HT2A receptors
[29]. This response has been reported to be enhanced by
acute inhibition of 5-HT reuptake by SSRIs [30]. By con-
trast, DOI, which has an approximately equal affinity for
5-HT2A, 5-HT2B and 5-HT2C receptors, is considered to
induce a head-twitch response by a direct agonistic
effect on 5-HT2A receptors, because a DOI-induced
head-twitch response is blocked by selective 5-HT2A an-
tagonists but not by 5-HT2B/2C antagonists [29,31] and
is not modified by SSRIs [17,31]. The present study con-
firmed that the oral administration of the SSRI fluvox-
amine (10 mg/kg), which inhibits the 5-HT reuptake
and increases extracellular 5-HT concentration in the
brain [32], augments the head twitches induced by
5-HTP but does not change those induced by DOI. In
contrast, MAK significantly decreased the number ofFigure 4 Effects of MAK on 5-HTP-induced head twitches.
Results are the mean ± S.E.M. of the number of head twitches for a
30-min observation period. The number of rats per group was: control
group, n = 6; MAK-treated group, n = 6; fluvoxamine-treated group,
n = 6. **P < 0.01 compared with the control group, one-way analysis of
variance followed by Tukey’s test.
Figure 5 Effects of MAK on DOI-induced head twitches. Results
are the mean ± S.E.M. of the number of head twitches for a 30-min
observation period. The number of rats per group was: control
group, n = 6; MAK-treated group, n = 6; fluvoxamine-treated group,
n = 6. **P < 0.01 compared with the control group, one-way analysis
of variance followed by Tukey’s test.
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duced by 5-HTP. These results suggest that MAK exerts
a 5-HT2A receptor inhibitory effect rather than a 5-HT
reuptake-inhibitory effect. The results for MAK are simi-
lar to those from a previous study that indicated that the
antidepressant nefazodone (which is a potent 5-HT2A
antagonist with a low affinity for serotonin transporters)
significantly attenuated the head twitches induced by
DOI but did not affect those induced by 5-HTP [17].
Previous studies have shown that the 5-HT1A agonist 8-
OH-DPAT also attenuates the DOI-induced head twitch
response in rats and mice [31]. However, it is unlikely
that the effect of MAK involves the 5-HT1A mecha-
nisms, because we observed no serotonin syndrome-like
behaviors (such as flat body posture, hind limb abduc-
tion, and forepaw treading) that are induced primarily
by an agonism at 5-HT1 receptor subtypes [31] in the
MAK-treated rats. Studies on the action of G. lucidum
on serotonin receptors are lacking, but a recent study fo-
cusing on the antipruritic effect of a methanol extract of
the fruiting body of G. lucidum showed that the extract
inhibits the scratching behavior induced by intradermal
administration of serotonin or a 5-HT2 receptor agonist
alpha-methyl-5-HT in mice [33]. Taken together, the find-
ings of the present study suggest that the antidepressant-
like effect of MAK might be mediated (at least in part) by
5-HT2A receptor inhibition in the brain. On the other
hand, the antidepressant mechanism of MAK may also in-
volve the noradrenergic system in addition to the seroto-
nergic system. Future studies will also address the role of
the noradrenergic system in the mechanism of action of
MAK.Studies in humans and in animal models of depression
have provided evidence that oxidative stress and subse-
quent inflammatory neurodegenerative responses have
an important pathophysiological role in depression [34].
Neuronal cells are known to be especially prone to
oxidative damage because of their higher oxygen con-
sumption and inadequate antioxidant defense systems
to reactive oxygen species [35]. Several studies have
demonstrated lowered antioxidant defenses (such as
decreases in the levels of antioxidants and antioxidant
enzymes) and increased oxidative stress (such as in-
creased levels of lipid peroxidation and DNA damage) in
patients with major depression [34]. Moreover, anti-
depressant drugs have been demonstrated to ameliorate
oxidative disturbances in depressed patients [36] and
chronically stressed animals [37]. Previously, we reported
that MAK exerts radical-scavenging activity and sup-
presses lipid peroxidation in a concentration-dependent
manner in vitro [38]. Additionally, oral administration of
MAK (1 g/kg/day) for 2 weeks has been shown to
normalize the augmentation of oxidative stress and antioxi-
dant enzyme (superoxide dismutase, catalase, and gluta-
thione peroxidase) activities in streptozotocin-induced
diabetic rat brains [10]. Furthermore, we demonstrated that
MAK could prevent ischemia–reperfusion-induced oxi-
dative damage and subsequent inflammatory responses
in neuronal cells, and reduce the size of cerebral infarcts
in animal models [10,11]. Therefore, the antioxidant
and neuroprotective activities of MAK could contribute
(at least in part) to its antidepressant-like effects. How-
ever, it is uncertain how such anti-oxidative effects
brought about by acute administration of MAK affect
the behaviors in the tests we observed in this report.
MAK has a 17-year history of making appreciable con-
tributions to consumers’ health as a safe, functional
food. In the past, there was no report suggesting that
MAK had potential acute or long-term toxicities in
consumers. The safety of MAK has been confirmed by
in vitro toxicological evaluation and animal toxicity stud-
ies. Additionally, we showed previously that chronic
treatment of MAK (1 g/kg for 9 weeks) had no effect on
body-weight gain, levels of aspartate aminotransferase,
alanine aminotransferase, triglycerides and total choles-
terol in the serum, or the histochemistry in the brains,
livers and kidneys of healthy mice [38]. Therefore, single
administration of 1 g/kg MAK used in the present study
is considered to have little or no toxicity. MAK is com-
posed of bagasse and defatted rice bran that is over-
grown with G. lucidum mycelia, which is considered to
contain various bioactive substances, including triterpenes,
polysaccharides and water-soluble lignin. Recently, triter-
penes from Bacopa monnieri [39] and Centella asiatica
[40] as well as polysaccharides from Panax ginseng [41]
were shown to have antidepressant-like effects in animals.
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that exert similar pharmacological effects. Future works
need to be conducted to identify the substances that con-
tribute to the antidepressant effects of MAK.
Conclusion
In summary, the present study demonstrated that MAK
has antidepressant-like potential, which is most likely as
a result of the antagonism of 5-HT2A receptors, and pos-
sesses anxiolytic-like effects toward memory-dependent
and/or stress-induced anxiety in rats. Hereafter, further
chemical and pharmacological analyses of MAK will be
conducted to isolate and characterize the active ingredi-
ents responsible for these antidepressant-like effects.
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